HGHRX: Hartford Healthcare R3

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

HGHRX Hartford Healthcare R3


Profile

HGHRX - Profile

Vitals

  • YTD Return 0.8%
  • 3 Yr Annualized Return 8.3%
  • 5 Yr Annualized Return 0.1%
  • Net Assets $1.4 B
  • Holdings in Top 10 36.3%

52 WEEK LOW AND HIGH

$39.01
$32.93
$40.09

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.62%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 35.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $0
  • IRA N/A

Fund Classification


Distributions

  • YTD Total Return 0.8%
  • 3 Yr Annualized Total Return 10.1%
  • 5 Yr Annualized Total Return 5.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.62%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    The Hartford Healthcare Fund Class R3
  • Fund Family Name
    Hartford Mutual Funds
  • Inception Date
    Dec 22, 2006
  • Shares Outstanding
    N/A
  • Share Class
    Retirement
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Ann Gallo

Fund Description

Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP ("Wellington Management"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.


Get Updates About HGHRX

Sign up for Advisor Access to receive email updates about HGHRX competitors, news, CE accredited webcasts and more.


Categories

Performance

HGHRX - Performance

Return Ranking - Trailing

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
YTD 0.8% -4.5% 2.6% 20.93%
1 Yr 16.9% -0.9% 35.2% 33.61%
3 Yr 8.3%* -9.6% 25.9% 53.21%
5 Yr 0.1%* -10.4% 13.1% 45.19%
10 Yr 9.5%* -2.7% 16.9% 44.71%

* Annualized

Return Ranking - Calendar

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
2019 25.0% 5.7% 55.4% 21.01%
2018 -10.4% -25.3% 21.5% 74.77%
2017 15.3% -10.8% 43.9% 54.13%
2016 -17.2% -31.6% 6.9% 61.32%
2015 -1.6% -20.4% 13.8% 45.63%

Total Return Ranking - Trailing

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
YTD 0.8% -4.5% 2.6% 20.93%
1 Yr 16.9% -0.9% 35.2% 32.77%
3 Yr 10.1%* -9.6% 29.1% 47.71%
5 Yr 5.8%* -10.4% 16.0% 33.65%
10 Yr 13.3%* -2.7% 17.7% 38.82%

* Annualized

Total Return Ranking - Calendar

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
2019 25.0% 5.7% 55.4% 21.01%
2018 -10.4% -25.3% 22.2% 75.68%
2017 21.3% -10.8% 45.8% 44.95%
2016 -8.8% -26.4% 8.7% 31.13%
2015 12.1% -16.6% 15.2% 14.56%

NAV & Total Return History


Holdings

HGHRX - Holdings

Concentration Analysis

HGHRX Category Low Category High HGHRX % Rank
Net Assets 1.4 B 3.58 M 48.1 B 38.58%
Number of Holdings 109 18 399 18.60%
Net Assets in Top 10 494 M 71.5 K 17.4 B 39.53%
Weighting of Top 10 36.30% 21.3% 75.3% 63.57%

Top 10 Holdings

  1. Abbott Laboratories 4.60%
  2. Pfizer Inc 4.39%
  3. Medtronic PLC 4.21%
  4. Bristol-Myers Squibb Company 4.15%
  5. Thermo Fisher Scientific Inc 3.62%
  6. Eli Lilly and Co 3.31%
  7. Boston Scientific Corp 3.27%
  8. UnitedHealth Group Inc 3.12%
  9. Anthem Inc 2.83%
  10. AstraZeneca PLC ADR 2.80%

Asset Allocation

Weighting Return Low Return High HGHRX % Rank
Stocks
96.63% 48.12% 103.54% 78.29%
Cash
3.37% 0.00% 51.88% 16.28%
Preferred Stocks
0.00% 0.00% 1.08% 24.81%
Other
0.00% -27.41% 5.17% 50.39%
Convertible Bonds
0.00% 0.00% 1.54% 23.26%
Bonds
0.00% 0.00% 20.60% 20.16%

Stock Sector Breakdown

Weighting Return Low Return High HGHRX % Rank
Healthcare
100.00% 58.44% 100.00% 2.33%
Utilities
0.00% 0.00% 0.00% 9.30%
Technology
0.00% 0.00% 16.36% 34.11%
Real Estate
0.00% 0.00% 5.84% 17.05%
Industrials
0.00% 0.00% 2.40% 17.83%
Financial Services
0.00% 0.00% 6.09% 27.91%
Energy
0.00% 0.00% 0.43% 13.95%
Communication Services
0.00% 0.00% 1.02% 13.95%
Consumer Defense
0.00% 0.00% 36.20% 17.05%
Consumer Cyclical
0.00% 0.00% 10.50% 15.50%
Basic Materials
0.00% 0.00% 2.02% 28.68%

Stock Geographic Breakdown

Weighting Return Low Return High HGHRX % Rank
US
79.07% 48.12% 99.93% 61.24%
Non US
17.56% 0.00% 39.36% 34.11%

Expenses

HGHRX - Expenses

Operational Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.62% 0.10% 9.84% 37.80%
Management Fee 0.85% 0.09% 1.30% 68.99%
12b-1 Fee 0.50% 0.00% 1.00% 52.86%
Administrative Fee 0.20% 0.03% 0.40% 78.72%

Sales Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 35.00% 0.00% 341.00% 36.29%

Distributions

HGHRX - Distributions

Dividend Yield Analysis

HGHRX Category Low Category High HGHRX % Rank
Dividend Yield 0.00% 0.00% 5.32% 20.16%

Dividend Distribution Analysis

HGHRX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

HGHRX Category Low Category High HGHRX % Rank
Net Income Ratio -0.62% -2.24% 2.12% 77.17%

Capital Gain Distribution Analysis

HGHRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

HGHRX - Fund Manager Analysis

Managers

Ann Gallo


Start Date

Tenure

Tenure Rank

May 01, 2000

19.68

19.7%

Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.

Robert Deresiewicz


Start Date

Tenure

Tenure Rank

May 01, 2000

19.68

19.7%

Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.

Jean Hynes


Start Date

Tenure

Tenure Rank

May 01, 2000

19.68

19.7%

Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.59 22.31 9.83 19.68